Table 5:
Predictors of 1-year and >1 to 5 year survival for endometrial cancer patients with high grade disease who survival at least 3 month stratified by FIGO stage
| FIGO Stage I - II | FIGO Stage III- IV | |||||||
|---|---|---|---|---|---|---|---|---|
| 1 year survival | >1 – 5 year survival | 1 year survival | >1 – 5 year survival | |||||
| Predictor Variable | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI |
|
| ||||||||
| Race/Ethnicity | ||||||||
|
| ||||||||
| NHW | Ref | Ref | Ref | Ref | ||||
|
| ||||||||
| NHB | 1.42 | 1.14–1.76 | 1.34 | 1.18–1.52 | 1.19 | 0.98–1.44 | 1.27 | 1.07–1.50 |
|
| ||||||||
| Hispanic | 0.70 | 0.46–1.07 | 0.88 | 0.72–1.07 | 1.24 | 0.94–1.64 | 1.10 | 0.87–1.41 |
|
| ||||||||
| Surgical Complications | ||||||||
|
| ||||||||
| None | Ref | Ref | Ref | Ref | ||||
|
| ||||||||
| 1 | 1.31 | 1.08–1.60 | 1.20 | 1.09–1.33 | 1.36 | 1.14–1.63 | 1.23 | 1.07–1.42 |
|
| ||||||||
| 2 | 1.45 | 1.13–1.87 | 1.29 | 1.13–1.49 | 1.36 | 1.10–1.68 | 1.32 | 1.12–1.56 |
|
| ||||||||
| 3+ | 2.21 | 1.76–2.76 | 1.30 | 1.13–1.50 | 1.73 | 1.42–2.11 | 1.33 | 1.12–1.58 |
|
| ||||||||
| p-trend | <0.001 | <0.001 | <0.001 | <0.001 | ||||
|
| ||||||||
| Adjuvant Treatment | ||||||||
|
| ||||||||
| Adjuvant treatment without delay | Ref | Ref | Ref | Ref | ||||
|
| ||||||||
| Treatment Delay | 1.24 | 0.91–1.68 | 1.15 | 0.97–1.36 | 1.31 | 0.97–1.76 | 0.96 | 0.74–1.23 |
|
| ||||||||
| No Adjuvant Treatment | 1.02 | 0.86–1.21 | 0.83 | 0.76–0.91 | 2.17 | 1.84–2.56 | 0.92 | 0.78–1.08 |
|
| ||||||||
| Age Group | ||||||||
|
| ||||||||
| Ordinal (5 year groups) | 1.05 | 1.04–1.06 | 1.04 | 1.04–1.05 | 1.02 | 1.00–1.03 | 1.02 | 1.01–1.03 |
|
| ||||||||
| Histology | ||||||||
|
| ||||||||
| Endometrioid | Ref | Ref | Ref | Ref | ||||
|
| ||||||||
| Non-Endometrioid | 1.71 | 1.44–2.03 | 1.28 | 1.17–1.39 | 1.23 | 1.05–1.45 | 1.26 | 1.11–1.44 |
|
| ||||||||
| Marital Status | ||||||||
|
| ||||||||
| Married or equivalent | Ref | Ref | Ref | Ref | ||||
|
| ||||||||
| S/D/W | 1.27 | 1.07–1.51 | 1.17 | 1.07–1.27 | 1.12 | 0.96–1.31 | 1.11 | 0.98–1.25 |
|
| ||||||||
| Comorbidity Score | ||||||||
|
| ||||||||
| None | Ref | Ref | Ref | Ref | ||||
|
| ||||||||
| 1 | 1.03 | 0.84–1.28 | 1.08 | 0.98–1.20 | 1.08 | 0.90–1.30 | 1.14 | 0.99–1.31 |
|
| ||||||||
| 2 | 1.37 | 1.09–1.71 | 1.31 | 1.17–1.48 | 1.05 | 0.85–1.29 | 1.21 | 1.03–1.43 |
|
| ||||||||
| 3+ | 1.61 | 1.28–2.02 | 1.33 | 1.17–1.51 | 1.28 | 1.04–1.58 | 1.25 | 1.05–1.49 |
|
| ||||||||
| Surgery Type | ||||||||
|
| ||||||||
| Open | Ref | Ref | Ref | Ref | ||||
|
| ||||||||
| MIS | 0.91 | 0.74–1.12 | 1.02 | 0.91–1.13 | 0.83 | 0.67–1.04 | 0.89 | 0.75–1.05 |
|
| ||||||||
| Lymphadenectomy | ||||||||
|
| ||||||||
| Not Done | Ref | Ref | Ref | Ref | ||||
|
| ||||||||
| 1–10 nodes examined | 0.74 | 0.61–0.91 | 0.95 | 0.85–1.05 | 0.80 | 0.67–0.94 | 0.77 | 0.67–0.89 |
|
| ||||||||
| >10 nodes examined | 0.71 | 0.58–0.85 | 0.73 | 0.66–0.81 | 0.58 | 0.49–0.70 | 0.66 | 0.57–0.75 |
|
| ||||||||
| Urban Rural Indicator | ||||||||
|
| ||||||||
| All urban | Ref | Ref | Ref | Ref | ||||
|
| ||||||||
| Mostly urban | 0.98 | 0.80–1.20 | 1.07 | 0.97–1.19 | 1.00 | 0.84–1.20 | 1.15 | 1.00–1.33 |
|
| ||||||||
| Mostly rural | 1.37 | 1.03–1.83 | 0.90 | 0.75–1.08 | 1.10 | 0.82–1.48 | 1.27 | 1.01–1.61 |
|
| ||||||||
| All rural | 1.02 | 0.76–1.36 | 1.03 | 0.89–1.20 | 1.07 | 0.82–1.40 | 1.06 | 0.85–1.32 |
|
| ||||||||
| Diagnosis Year (continuous) | 0.98 | 0.96–0.99 | 1.00 | 0.99–1.01 | 1.00 | 0.98–1.01 | 1.00 | 0.99–1.02 |
NHW: Non-Hispanic White; NHB: Non-Hispanic Black